Differences in fabry cardiomyopathy between female and male patients: Consequences for diagnostic assessment

JACC: Cardiovascular Imaging

Volumn 4, Issue 6, 2011, Pages 592-601

  Niemann, Markus ^a,b   Herrmann, Sebastian ^a,b   Hu, Kai ^a   Breunig, Frank ^a   Strotmann, Jörg ^a   Beer, Meinrad ^a   MacHann, Wolfram ^a   Voelker, Wolfram ^a   Ertl, Georg ^a,b   Wanner, Christoph ^a   Weidemann, Frank ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

cardiomyopathy; echocardiography; Fabry disease; hypertrophy

Indexed keywords

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIAC PATIENT; CARDIOGRAPHY; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; COHORT ANALYSIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FABRY DISEASE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HUMAN; IMAGE ENHANCEMENT; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; PHYSICAL STRESS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER, PULSED; FABRY DISEASE; FEMALE; FIBROSIS; GERMANY; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 79958810192     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2011.01.020     Document Type: Article

References (31)

1. Desnick R, Ionnou Y, Eng C. Fabry disease: alpha galactosidase A deficiency. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw Hill, 1995:2741-84.
2. Ropers HH, Wienker TF, Grimm T, Schroetter K, Bender K. Evidence for preferential X-chromosome inactivation in a family with Fabry disease. Am J Hum Genet 1977;29:361-70. (Pubitemid 8148061)
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-75. (Pubitemid 33032933)
4. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 2001;24 Suppl 2:13-4, discussion 11-2.
5. Moller AT, Jensen TS. Neurological manifestations in Fabry's disease. Nat Clin Pract Neurol 2007;3:95-106. (Pubitemid 46237916)
6. Moller AT, Feldt-Rasmussen U, Rasmussen AK, et al. Small-fibre neuropathy in female Fabry patients: reduced allodynia and skin blood flow after topical capsaicin. J Peripher Nerv Syst 2006;11:119-25. (Pubitemid 43894078)
7. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42. (Pubitemid 38406640)
8. Maier EM, Osterrieder S, Whybra C, et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl 2006;95:30-8. (Pubitemid 43739092)
9. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey. Eur Heart J 2007;28:1228-35. (Pubitemid 47343855)
10. Wanner C. Fabry disease model: a rational approach to the management of Fabry disease. Clin Ther 2007;29 Suppl A:S2-5.
11. Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-301. (Pubitemid 37174405)
12. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524-9.
13. Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005;26:1221-7. (Pubitemid 40863129)
14. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151-5.
15. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 2006;8:479-82.
16. Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006;97:1515-8.
17. Pieroni M, Chimenti C, Russo A, Russo MA, Maseri A, Frustaci A. Tissue Doppler imaging in Fabry disease. Curr Opin Cardiol 2004;19:452-7. (Pubitemid 39222960)
18. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003;107:1978-84. (Pubitemid 36506070)
19. Gange CA, Link MS, Maron MS. Utility of cardiovascular magnetic resonance in the diagnosis of Anderson-Fabry disease. Circulation 2009;120:e96-7.
20. Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002;40:1668-74. (Pubitemid 35253646)
21. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multiorgan system involvement. Genet Med 2006;8:539-48. (Pubitemid 44402030)
22. Breunig F, Weidemann F, Beer M, et al. Fabry disease: diagnosis and treatment. Kidney Int Suppl 2003;63 Suppl 84: S181-5.
23. Takenaka T, Teraguchi H, Yoshida A, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 2008;51:50-9. (Pubitemid 351699928)
24. Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivananthan MU. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging 2003;17:323-9. (Pubitemid 36259246)
25. Alfakih K, Reid S, Jones T, Sivananthan M. Assessment of ventricular function and mass by cardiac magnetic resonance imaging. Eur Radiol 2004; 14:1813-22. (Pubitemid 39386630)
26. Cain PA, Ahl R, Hedstrom E, et al. Age and gender specific normal values of left ventricular mass, volume and function for gradient echo magnetic resonance imaging: a cross sectional study. BMC Med Imaging 2009;9:2.
27. Sandstede J, Lipke C, Beer M, et al. Age-and gender-specific differences in left and right ventricular cardiac function and mass determined by cine magnetic resonance imaging. Eur Radiol 2000;10:438-42. (Pubitemid 30145755)
28. Strotmann J, Weidemann F, Breunig F, Knoll A, Wanner C, Ertl G. Morbus Fabry of the heart. Why should cardiologists care? Z Kardiol 2005;94:557-63.
29. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986;7:1157-61. (Pubitemid 16103117)
30. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000;139:1101-8. (Pubitemid 30390343)
31. Weidemann F, Niemann M, Herrmann S, et al. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur Heart J 2007;28:3020-6. (Pubitemid 350262257)